Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.

Date publication

avril 2026

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BIBEAU Frédéric

Tous les auteurs :
de la Fouchardière C, Zaanan A, de Montfort A, Cohen R, Le Sourd S, Tougeron D, Soularue E, Dubreuil O, Williet N, Samalin-Scalzi E, Piessen G, Hautefeuille V, Jary M, Ben Abdelghani M, Evesque L, Rochigneux P, Blanc E, Pérol D, Bibeau F, Coutzac C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41980235

Résumé

Mismatch repair deficiency (dMMR) or microsatellite instability (MSI) represents a distinct phenotype among solid tumors resulting in the generation of highly immunogenic neoantigens. Pembrolizumab has been approved in first-line unresectable or metastatic dMMR/MSI colorectal cancers (CRC). We aimed to assess efficacy and tolerance of perioperative pembrolizumab in dMMR/MSI CRC.

Référence

J Clin Oncol. 2026 04 14;:JCO2502169